Abstract BACKGROUND The CHEST Antithrombotic Therapy for Venous Thromboembolism
Disease evidencebased guidelines are now updated in a more frequent, focused manner …

Abstract The Spanish Society of Medical Oncology (SEOM) last published clinical guidelines
on venous thromboembolism (VTE) and cancer in 2019, with a partial update in 2020. In this …

BACKGROUND Deep vein thrombosis (DVT) of the lower extremity is one of the most
common postoperative complications, especially after craniocerebral surgery. DVT may lead …

Current guidelines suggest a 3‐month anticoagulant treatment course for isolated distal
deep vein thrombosis (IDDVT), but shorter durations of treatment are frequently prescribed …

Background The multicenter, open-label, randomized clinical trial ONCO DVT compared 3-
month and 12-month edoxaban treatment regimens for isolated distal deep vein thrombosis …

The balance between bleeding and cardiovascular events by dual antiplatelet treatment
(DAPT) is a critical concern in patients undergoing percutaneous coronary intervention …

Isolated distal deep vein thrombosis (DVT) represents up to 50% of all lower limb DVT in
ultrasound series and is a frequent medical condition, which management is not well …

Cancer-associated thrombosis (CAT) is a primary cardiovascular complication encountered
during cancer treatment, and venous thromboembolism (VTE) could be the most prevalent …

Abstract Background The ONCO DVT study revealed superiority of 12-month relative to 3-
month edoxaban treatment for the thrombotic risk in cancer-associated isolated distal deep …

Abstract Background The ONCO DVT study revealed the superiority of 12-month relative to 3-
month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) …